Climb Bio, Inc. (CLYM) Dividend History

Climb Bio, Inc. (CLYM) is a biotechnology company focused on developing innovative therapies targeting neurodegenerative diseases. The company leverages its proprietary platforms to discover and advance drug candidates aimed at addressing unmet medical needs in neurosciences.

2801 Centerville Road 1st Floor, Wilmington, DE, 19808
Phone: 877-354-3689
Website: https://www.climbbio.com

Dividend History

Climb Bio, Inc. currently does not pay dividends

Company News

  • Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Climb Bio, a clinical-stage biotech company, announced progress in its pipeline, including the initiation of clinical trials for its lead candidate budoprutug in 2025 and the advancement of CLYM116 towards IND-enabling studies. The company also appointed two seasoned biotech leaders to its board of directors.

    GlobeNewswire Inc.
Page data last updated 08/19/2025 16:54:11 UTC